Volume 24, Number 3—March 2018
Research
Acquired Resistance to Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000–2015
Figure 3

Figure 3. Number and proportion of tuberculosis patients with acquired drug resistance, by drug, England, Wales, and Northern Ireland, 2000–2015. AMK, amikacin; AZM, azithromycin; CIP, ciprofloxacin; CLR, clarithromycin; CPM, capreomycin; CSN, cycloserine; EMB, ethambutol; ETH, ethionamide; KAN, kanamycin; INH, isoniazid; MXF, moxifloxacin; OXF, ofloxacin; PAS, para-aminosalicylic acid (bacteriostatic); PTO, prothionamide; PZA, pyrazinamide; RIF, rifampin; RFB, rifabutin; STR, streptomycin.